Prostate‐specific antigen nadir and testosterone level at prostate‐specific antigen failure following radiation and androgen suppression therapy for unfavorable‐risk prostate cancer and the risk of all‐cause and prostate cancer–specific mortality

Cancer ◽  
2021 ◽  
Author(s):  
Danielle S. Bitterman ◽  
Ming‐Hui Chen ◽  
Jing Wu ◽  
Andrew A. Renshaw ◽  
Marian Loffredo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Testosterone Level ◽  
Specific Antigen ◽  
Specific Mortality ◽  
Risk Prostate Cancer ◽  
Cancer Specific Mortality ◽  
Androgen Suppression

Time to Prostate Specific Antigen Recurrence After Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality

2006 ◽  
Vol 176 (4) ◽  
pp. 1404-1408 ◽  
Author(s):  
Stephen J. Freedland ◽  
Elizabeth B. Humphreys ◽  
Leslie A. Mangold ◽  
Mario Eisenberger ◽  
Alan W. Partin
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Specific Mortality ◽  
Cancer Specific Mortality

Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era

2003 ◽  
Vol 21 (11) ◽  
pp. 2163-2172 ◽  
Author(s):  
Anthony V. D’Amico ◽  
Judd Moul ◽  
Peter R. Carroll ◽  
Leon Sun ◽  
Deborah Lubeck ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Risk Groups ◽  
The United States ◽  
Localized Prostate Cancer ◽  
Institutional Setting ◽  
Psa Failure ◽  
Specific Mortality ◽  
Cancer Specific Mortality

Purpose: To determine whether pretreatment risk groups shown to predict time to prostate cancer–specific mortality (PCSM) after treatment at a single institution retained that ability in a multi-institutional setting. Patients and Methods: From 1988 to 2002, 7,316 patients treated in the United States at 44 institutions with either surgery (n = 4,946) or radiation (n = 2,370) for clinical stage T1c-2, N0 or NX, M0 prostate cancer made up the study cohort. A Cox regression analysis was performed to determine the ability of pretreatment risk groups to predict time to PCSM after treatment. The relative risk (RR) of PCSM and 95% confidence intervals (CIs) were calculated for the intermediate- and high-risk groups relative to the low-risk group. Results: Estimates of non-PCSM 8 years after prostate-specific antigen (PSA) failure were 4% v 15% (surgery versus radiation; Plog rank = .002) compared with 13% v 18% (surgery versus radiation; Plog rank = .35) for patients whose age at the time of PSA failure was less than 70 as compared with ≥ 70 years, respectively. The RR of PCSM after treatment for surgery-managed patients with high- or intermediate-risk disease was 14.2 (95% CI, 5.0 to 23.4; PCox < .0001) and 4.9 (95% CI, 1.7 to 8.1; PCox = .0037), respectively. These values were 14.3 (95% CI, 5.2 to 24.0; PCox < .0001) and 5.6 (95% CI, 2.0 to 9.3; PCox = .0012) for radiation-managed patients. Conclusion: This study provided evidence to support the prediction of time to PCSM after surgery or radiation on the basis of pretreatment risk groups for patients with clinically localized prostate cancer managed during the PSA era.

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality

Urology ◽  
2006 ◽  
Vol 68 (2) ◽  
pp. 342-347 ◽  
Author(s):  
Jason A. Efstathiou ◽  
Ming-Hui Chen ◽  
William J. Catalona ◽  
David G. McLeod ◽  
Peter R. Carroll ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Specific Mortality ◽  
Cancer Specific Mortality
Sign in / Sign up

Export Citation Format

Share Document